ESMO/LinkedIn
Mar 20, 2025, 08:31
Nirogacestat shows lasting benefits for desmoid tumors – ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“In an updated analysis presented at ESMO Rare Cancers25, nirogacestat increased the objective response rate from 34.3% (for up to 1 year of treatment) to 45.7% (for up to 4 years of treatment) in patients with progressing Desmoid Tumours in the DeFi trial.
The incidence and severity of adverse events decreased after year 1. Real-world findings with nirogacestat were also presented from the DeNi study, which may help delineate which patients benefit most from treatment.
More results in the ESMO Daily Reporter.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 14:51
May 1, 2025, 14:30
May 1, 2025, 14:00
May 1, 2025, 13:26
May 1, 2025, 13:03
May 1, 2025, 12:22